Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Viral Hepatitis Market Size From 2025 to 2034?
The market size for viral hepatitis has been experiencing consistent growth over recent years. The projections show an increase from $16.21 billion in 2024 to $16.77 billion in 2025, which represents a compound annual growth rate (CAGR) of 3.4%. The growth witnessed in the past can be credited to aspects such as the development of vaccines, blood screening programs, antiviral drugs, and initiatives concerning global health.
Continued growth is anticipated in the viral hepatitis market over the upcoming years, with expectations of reaching a size of$19.71 billion by 2029, boasting a compound annual growth rate (CAGR) of 4.1%. The predicted surge during the forecast period is likely due to factors such as health equity initiatives, combination therapies, public health laws, and better access to treatment. The period is also expected to see major trends such as digital health tools, personalized treatment plans, artificial intelligence in disease surveillance, and focused efforts to micro-eliminate hepatitis C.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp
Which Factors and External Forces Are Driving Demand in the Viral Hepatitis Market?
The escalating incidence of hepatitis is anticipated to bolster the expansion of the viral hepatitis market in the near future. The disease, characterized by liver inflammation, can be triggered by several viruses as well as non-viral substances, leading to potential health complications. Hepatitis A, B, C, D, and E are the viruses that lead to viral hepatitis, which in turn cause inflammation and harm to the liver. For example, the European Centre for Disease Prevention and Control, a health agency headquartered in Sweden, reported in April 2024 that the occurrence of Hepatitis B Virus (HBV) infection had risen to 28,855 cases across 30 EU/EEA member nations in 2022. This marks a significant 78% surge from the 16,187 cases documented in 2021. More so, the number of cases in 2022, reaching up to 28,420, corresponds to a crude rate of 8.5 cases per 100,000 individuals. Consequently, the mounting occurrence of hepatitis is set to fuel the growth of the viral hepatitis market.
Which Segments in the Viral Hepatitis Offer the Most Growth?
The viral hepatitismarket covered in this report is segmented –
1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Hepatitis A: Acute Hepatitis A; Chronic Hepatitis A
2) By Hepatitis B: Acute Hepatitis B; Chronic Hepatitis B; Hepatitis B Carrier
3) By Hepatitis C: Acute Hepatitis C; Chronic Hepatitis C
4) By Other Disease Types: Hepatitis D; Hepatitis E
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Viral Hepatitis Market?# Market?
North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theViral Hepatitis Market’s Growth?
Firms in the viral hepatitis industry are progressing new pharmaceuticals and innovations to retain their market standing. The development of innovative drugs enhances scientific comprehension by providing a deeper understanding of disease processes and speeding up the creation of novel treatments. For example, Gilead Sciences Inc., an American biopharmaceutical firm, reported in November 2022 that the Food and Drug Administration (FDA) had approved the supplemental new medicine application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a daily treatment for chronic hepatitis B virus (HBV) infection in children 12 years and older suffering from compensated liver disease. The authorization of Vemlidy was backed by the results from the 24-week Phase 2 clinical trial in this pediatric patient group.
View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report
What Are the Key Elements That Define the Viral Hepatitis Market?
Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model